AngioDynamics (NASDAQ:ANGO) Releases FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of -0.420–0.380 for the period, compared to the consensus estimate of -0.410. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $284.4 million. AngioDynamics also updated its FY25 guidance to ($0.42)-($0.38) EPS.

AngioDynamics Stock Performance

Shares of ANGO opened at $6.37 on Friday. The business has a 50-day moving average of $7.51 and a 200 day moving average of $6.62. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $8.25. The firm has a market cap of $255.15 million, a P/E ratio of -1.32 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.11. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The company had revenue of $71.00 million during the quarter, compared to analyst estimates of $70.86 million. During the same quarter last year, the firm posted $0.02 EPS. The firm’s revenue for the quarter was down 22.1% on a year-over-year basis. As a group, research analysts predict that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ANGO has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a buy rating and set a $14.00 target price on shares of AngioDynamics in a report on Friday, September 20th. Canaccord Genuity Group cut their price objective on AngioDynamics from $18.00 to $13.00 and set a buy rating for the company in a report on Wednesday, July 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $12.25.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.